EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

04 May 2018
EMA/198910/2018
EMEA/H/C/001240

Public statement

Vibativ

Withdrawal of the marketing authorisation in the European Union

On 23 March 2018, the European Commission withdrew the marketing authorisation for Vibativ (telavancin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Theravance Biopharma Ireland Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Vibativ was granted marketing authorisation in the EU on 2 September 2011 for treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant *Staphylococcus aureus* (MRSA). The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2016.

The European Public Assessment Report (EPAR) for Vibativ will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact